Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Increased by Ashton Thomas Securities LLC

Ashton Thomas Securities LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 8.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,797 shares of the life sciences company’s stock after buying an additional 228 shares during the quarter. Ashton Thomas Securities LLC’s holdings in Illumina were worth $365,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. raised its position in shares of Illumina by 426.0% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after purchasing an additional 12,521 shares during the period. Jupiter Asset Management Ltd. purchased a new stake in Illumina during the first quarter valued at about $4,527,000. US Bancorp DE boosted its holdings in shares of Illumina by 33.9% in the first quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock worth $4,339,000 after buying an additional 8,001 shares during the period. Cetera Advisors LLC purchased a new position in shares of Illumina in the first quarter worth approximately $610,000. Finally, Weybosset Research & Management LLC raised its holdings in shares of Illumina by 92.0% during the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after acquiring an additional 8,650 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on ILMN shares. StockNews.com began coverage on Illumina in a research report on Thursday, August 29th. They issued a “buy” rating for the company. Leerink Partners lifted their target price on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Barclays increased their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group upped their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Finally, Piper Sandler decreased their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $163.71.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $151.50 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business has a 50 day moving average price of $138.09 and a 200 day moving average price of $123.55. The company has a market cap of $24.03 billion, a price-to-earnings ratio of -15.21 and a beta of 1.13. Illumina, Inc. has a twelve month low of $92.26 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the firm posted $0.33 earnings per share. Illumina’s revenue was down 3.5% compared to the same quarter last year. Research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.